Study of Safety and Efficacy on New Peritoneal Dialysis Solutions

Phase 2

Withdrawn

• Conditions: End-Stage Renal Disease
• Interventions: Drug: PD solution for diurnal exchanges; Drug: PD solution for nocturnal exchanges

• Registration Number: NCT00858182
• Lead Sponsor: Iperboreal Pharma Srl

Brief Summary

A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile. Study hypothesis is to evaluate the possibility to formulate PD solutions containing xylitol and L-carnitine as osmotic agents to partially replace glucose.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-03-06
• Study First Submitted QC: 2009-03-06
• Study First Posted: 2009-03-09
• Study Start: 2009-05
• Primary Completion: 2012-10
• Study Completion: 2013-01
• Status Verified: 2013-03
• Last Update Submitted: 2019-06-24
• Last Update Posted: 2019-06-26

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Age ≥18 years;
• Diagnosis of ESRD treated for at least three month with CAPD, as stated by the medical staff of the center;
• CAPD treatment with 2.27% of glucose solution for the nocturnal exchange;
• Stable clinical condition within four weeks before screening period, certified by medical/surgical history, physical examination and laboratory exploration;
• Hemoglobin level ≥9g/dL;
• Residual diuresis ≤800mL;
• Absence of acute peritonitis and/or peritoneal catheter infection (either exit site or subcutaneous tunnel) episodes within three months before selection;
• Stable peritoneal permeability, as confirmed by a PET between 0.50 and 0.81 during previous three months and at day 0 of the screening period;
• Total urea Kt/V >1.5 per week at a control during previous three months and at day 0 of the screening period and/or minimal total creatinine clearance of 45 liter/week at a control during previous three months and at day 0 of the screening period; 1- To understand and sign an informed consent form.

For patients who will be included in Group B, the following criteria must be fulfilled too:

• Be treated with Extraneal (nocturnal exchange bag solution) for at least 1 month
• Be treated with 2 or 3 diurnal exchange bag solutions (solution bags with 1.36% or 2.27% glucose) and one nocturnal exchange bag solution (Extraneal)

Exclusion Criteria

• History of alcohol or drug abuse in the last six months before selection for the study;
• Androgen therapy in the last six months before selection;
• Active infections;
• History of congestive heart failure stage III and IV NYHA;
• History of major cardiovascular events like stroke, acute myocardial infarction, coronary or other arterial revascularization procedures in the last three months before selection;
• Clinically relevant cardiac arrhythmia;
• Clinically relevant abnormalities of functional hepatic tests;
• Therapy with L-carnitine or its derivatives in the last three months before selection;
• Pregnancy, lactating women or female subjects of childbearing potential who do not use an effective method of contraception;
• Presence of relevant chronic medical conditions that could suggest exclusion of patient from the study or could interfere with assessment of study parameters, especially if the life expectation is less then one year;
• Participation in another clinical study within the past month;
• Known or supposed allergic reactions to L-carnitine or xylitol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group B	PD solution for diurnal exchanges	-
Group A	PD solution for nocturnal exchanges	-

Primary Outcome Measures

Name	Time	Method
To assess ultrafiltration efficacy of PD solutions containing L-Carnitine and Xylitol	4 weeks